VivoSeq
Ophthalmology

Non-Infectious Anterior Uveitis

6

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Non-Infectious Anterior Uveitis is an early-stage landscape with 6 programs across 6 companies. The most active players are Veloxis Pharmaceuticals, Tarsier Pharma, Lux Biosciences, Inc.. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

67/100

Completion Rate

80/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Veloxis Pharmaceuticals

1 program

Phase 2T

Tarsier Pharma

2 programs

Phase 3L

Lux Biosciences, Inc.

1 program

Phase 3E

Eyegate Pharmaceuticals, Inc.

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3AbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Terminated1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
Not yet recruiting·NNovaliq GmbH·Phase 2·NCT07285070·20 enrolled
A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
Completed·TTarsier Pharma·Phase 3·NCT05042609·142 enrolled
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
Completed·LLux Biosciences, Inc.·Phase 3·NCT00404885·108 enrolled
A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis
Completed·TTarsier Pharma·Phase 1/2·NCT04222712·16 enrolled
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
Completed·EEyegate Pharmaceuticals, Inc.·Phase 3·NCT02517619·251 enrolled
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
Terminated·AbbVie logoAbbVie·Phase 2/3·NCT00333996·5 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)